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and/or pathologically confirmed NMO or NMO spectrum 
disorder. These findings were compared to five cases with 
multiple sclerosis, five cases of choroid plexus papilloma, 
and five control cases without central nervous system dis-
ease. In the NMO cases, AQP4 immunoreactivity was 
reduced relative to control levels in the pia (91%; 21/23), 
ependyma (56%; 9/16), and choroid plexus epithelium 
(100%; 12/12). AQP4 immunoreactivity was normal in MS 
cases in these regions. Compared to MS, NMO cases also 
showed a focal pattern of pial and ependymal complement 
deposition and more pronounced microglial reactivity. In 
addition, AQP4 loss, microglial reactivity, and complement 
deposition colocalized along the pia and ependyma only in 
NMO cases. Within the choroid plexus, AQP4 loss was coin-
cident with C9neo immunoreactivity on epithelial cell mem-
branes only in NMO cases. These observations demonstrate 
that NMO immunopathology extends beyond perivascular 
astrocytic foot processes to include the pia, ependyma, and 
choroid plexus, suggesting that NMO IgG-induced patholog-
ical alterations at CSF–brain and blood–CSF interfaces may 
contribute to the occurrence of ventriculitis, leptomeningitis, 
and hydrocephalus observed among NMO patients. Moreo-
ver, disruption of the blood–CSF barrier induced by binding 
of NMO IgG to AQP4 on the basolateral surface of choroid 
plexus epithelial cells may provide a unique portal for entry 
of the pathogenic antibody into the central nervous system.
Keywords Choroid plexus · Leptomeninges · Astrocyte · 
Complement · Immunopathology · Hydrocephalus
Introduction
Neuromyelitis optica (NMO) is a disabling inflammatory 
disorder of the central nervous system (CNS) that is marked 
Abstract Pathogenic autoantibodies associated with neu-
romyelitis optica (NMO) induce disease by targeting aqua-
porin-4 (AQP4) water channels enriched on astrocytic end-
feet at blood–brain interfaces. AQP4 is also expressed at 
cerebrospinal fluid (CSF)–brain interfaces, such as the pial 
glia limitans and the ependyma and at the choroid plexus 
blood–CSF barrier. However, little is known regarding 
pathology at these sites in NMO. Therefore, we evaluated 
AQP4 expression, microglial reactivity, and complement 
deposition at pial and ependymal surfaces and in the fourth 
ventricle choroid plexus in 23 autopsy cases with clinically 
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by expression of a pathogenic IgG autoantibody directed 
against the ectodomain of aquaporin-4 (AQP4), the major 
water channel in the CNS [34, 35]. AQP4 functions to couple 
bidirectional fast water transport to active ion flux across the 
plasma membrane, thereby controlling astrocyte homeosta-
sis and CNS osmotic stability [76]. The enrichment of AQP4 
on astrocytic endfeet at the blood–brain barrier is consistent 
with a crucial role in maintaining physiological water balance 
and with responding to pathological perturbations of this bal-
ance associated with ischemia or trauma [75]. Early NMO 
pathology is characterized by the presence of reactive astro-
cytes, intramyelinic edema, loss of AQP4 expression, variable 
perivascular deposition of IgG and complement components, 
and granulocytic leukocyte infiltration [40, 61]. Advanced 
lesions demonstrate more profound complement deposi-
tion, loss of myelin, and astrocyte destruction. Astrocytic 
responses in NMO range from sublytic gliosis to overt lysis, 
and these responses are frequently observed in regions with-
out myelin loss, suggesting that NMO is a primary astrocy-
topathy associated with secondary demyelination [39]. Such a 
model for NMO pathogenesis is consistent with observations 
of water dyshomeostasis [62], lesion reversibility [41, 42, 80], 
and behavioral sequelae in NMO patients [59].
AQP4 is also expressed at the pial glia limitans, the 
ependyma, and the choroid plexus [53, 61]. Notably, dif-
ferential cell–cell junction expression at these barrier sites 
[78] may provide a unique route for NMO IgG to enter 
the cerebrospinal fluid (CSF) and access AQP4-expressing 
targets in the brain parenchyma. Recently, loss of AQP4 
expression was observed in cortical layer I in NMO tissue 
and was associated with cognitive impairment and a cor-
responding loss of neurons in cortical layer II [65]. This 
finding suggests that subpial AQP4 was targeted by NMO 
IgG and indicates that astrocytopathy outside of the typi-
cal periventricular lesion may have profound pathogenic 
and neurologic consequences. However, at present, little is 
known about the pathology of CSF–brain and blood–CSF 
barriers in NMO patients. Therefore, in this study, we ana-
lyzed astrocyte and microglia reactivity, AQP4 expression 
level, and complement deposition at these interfaces.
Materials and methods
Study design and series
This study was approved by the Institutional Review Board 
of Mayo Clinic, Rochester, MN (IRB 2067-99). Inclu-
sion criteria were (i) clinical and pathological diagnosis of 
NMO or NMOSD; (ii) sufficient archival tissue for patho-
logical analysis; and (iii) no evidence of alternative diagno-
sis. Twenty-three autopsy cases met the inclusion criteria 
(315 total tissue blocks) (Supplemental Figure 1). Table 1 
provides demographics for the patient cohort. As controls, 
we included five multiple sclerosis (MS) cases (79 blocks; 
4 relapsing remitting MS, 1 secondary progressive MS) 
and five control cases without known CNS disease (45 
blocks). As additional controls for choroid plexus disease, 
we included five hydrocephalus cases (five blocks) and 
five papilloma cases (five blocks). We analyzed supraten-
torial brain (including optic nerve), brain stem, cerebel-
lum, and spinal cord for histopathological abnormalities in 
the pial surface, ependyma, and choroid plexus. To reduce 
anatomical variability in the choroid plexus analysis, we 
specifically assessed the choroid plexus in the fourth ven-
tricle at the level of the medulla.
Neuropathological evaluation
Formalin-fixed paraffin-embedded 5 µm thick sections 
were stained with hematoxylin and eosin (H&E), Luxol 
fast blue, and periodic acid Schiff (LFB/PAS), and modi-
fied Bielschowsky silver. Immunohistochemistry was per-
formed with the avidin–biotin-complex method as previ-
ously reported [40], using primary antibodies against 
glial fibrillary acidic protein (GFAP, 1:100, DAKO, 
Denmark), neurofilament (1:800, steam antigen retrieval 
with citric acid buffer pH 6.0, DAKO, Denmark), AQP1 
(1:250; Santa Cruz), AQP4 (1:250, Sigma-Aldrich, USA), 
myelin proteolipid protein (PLP, 1:500, Serotec, Oxford, 
UK), KiM1P (pan-macrophage marker, 1:5000, from Dr. 
Wolfgang Bruck, Germany), complement C9 neo-anti-
gen (C9neo, monoclonal B7 and polyclonal, 1:200, from 
Professor Paul Morgan, Cardiff, UK), and human IgG 
gamma chain (1:200, DAKO, Denmark).
Table 1  Demographic and clinical summaries
Unless otherwise indicated values shown are median (range). Note: 
age of symptom onset and disease duration missing for one patient; 
number of clinical attacks missing for two patients; AQP4-IgG serol-
ogy missing for 14 patients
a Sera available for testing in nine patients. Other subjects either 
lacked sera or preceded the availability of serological testing
Characteristic Summary
Number of subjects 23
Sex, male:female 2:21
Age at symptom onset, years 49 (12–73)
Diagnosis, n (%)
 NMO 18 (78%)
 NMO spectrum disorder 5 (22%)
AQP4-IgG serostatus, positive:negativea 9:0
Number of clinical attacks 3 (2–7)
Disease duration, months 36 (8–240)
Age at death, years 52 (16–80)
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We systematically analyzed the pial surface, epend-
yma, and choroid plexus for histopathological alterations, 
and assessed AQP4 immunoreactivity, the pattern of mac-
rophage/microglial reaction, and the presence of C9neo 
deposition. The patterns observed in NMO tissue were 
compared to the corresponding anatomical areas in MS 
and controls. For quantitation of AQP4 loss, the entire pia 
available on the tissue block was assessed for AQP4 immu-
noreactivity. The pattern of AQP4 reactivity was defined as 
focal when loss was restricted to a single high-power field 
at 40X, or diffuse when extending beyond one such field. 
Because of variation in the extent of the diffuse involve-
ment and to help differentiate between the situation, where 
diffuse loss encompassed the bulk of the pial surface versus 
when the diffuse loss was relatively isolated, we catego-
rized the diffuse loss as occupying <25, 25–50, 50–75, or 
>75% of the total length of pia available for analysis.
Results
Pial glia limitans
At the pial surface of the cerebral cortex, normal 
control tissue showed minimal microglial reactivity 
(KiM1P expression) (Fig. 1a), abundant AQP4 immu-
noreactivity (Fig. 1d), and no evidence of complement 
C9neo deposition (Fig. 1g). Widespread microglial 
Fig. 1  Pial pathology in normal, MS, and NMO tissues. Supratento-
rial brain tissue from neurologically normal controls (a, d, g), MS (b, 
e, h), and NMO (c, f, i). Microglial reactivity is minimal at the pial 
interface in normal control tissue (a), prominent in MS meninges, 
with diffuse extension into the cortical parenchyma (b), and concen-
trated in the glial limitans and in the upper molecular layer (between 
arrowheads) in NMO (c). AQP4 immunoreactivity is abundant at 
the glia limitans in normal control (d) and MS (e) (arrows), but lost 
or markedly reduced along the cortical surface in NMO (f; between 
arrowheads). Complement C9neo immunoreactivity is not detected at 
the pia in normal control (g) or MS (h), but concentrated at the pia 
in NMO (i; between arrowheads). Immunohistochemistry for KiM1P 
(a–c), AQP4 (d–f), and C9neo (g–i). Meninges marked by block up 
pointing triangle. Scale bars 100 µm
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reactivity, in both the meninges and subpial cortex, was 
observed in MS tissue (Fig. 1b), but AQP4 immuno-
reactivity was normal (Fig. 1e) and C9neo deposition 
was not detected (Fig. 1h). In contrast, in NMO tissue, 
there was accumulation of reactive microglia (Fig. 1c), 
near complete loss of AQP4 immunoreactivity at the 
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CSF–brain interface (Fig. 1f) and deposition of C9neo 
in focal regions of the pial glia limitans (Fig. 1i).
In NMO spinal cord, foci of reactive microglia (Fig. 2a), 
AQP4 loss (Fig. 2b; compare to normal spinal cord in 
Fig. 2p), and C9neo deposition (Fig. 2c) were observed 
at the pial glia limitans. At the pial surface of the medulla 
oblongata, dystrophic astrocytes (Fig. 2d, e), reactive 
microglia (Fig. 2f), C9neo deposition (Fig. 2g), and AQP4 
loss (Fig. 2h) were observed within the context of pre-
served myelin (Fig. 2i). At the pial surface of the cerebel-
lum, meningeal eosinophils and neutrophils (Fig. 2j, m) 
were found in proximity to regions containing reactive 
microglia (Fig. 2k, n; compare to normal cerebellum in 
Fig. 2q) and decreased or absent AQP4 immunoreactivity 
(Fig. 2l, o; compare to normal cerebellum in Fig. 2r). At 
the cerebellar pia, there was a mild loss of astrocytic pro-
cesses (Supplementary Figure 2a, 2b), compared to normal 
cerebellum (Supplementary Figure 2c, 2d).
In 21 of 23 NMO cases (91%), AQP4 immunoreactivity 
was lost and/or decreased at the pia across multiple blocks 
examined from a given patient (Fig. 3a). All CNS regions 
exhibited AQP4 loss at the pia, most frequently in spinal 
cord (Fig. 3b, Supplementary Figure 3). Reduced AQP4 
immunoreactivity occurred in both a diffuse and focal pat-
tern (Fig. 4), with diffuse loss ranging from less than 25% 
of the sampled pia, to more than 75% of the region charac-
terized by AQP4 loss.
The majority (82%) of NMO cases exhibited reac-
tive microglia that were increased in both size and num-
ber (Supplementary Figure 4a, 4b). In cerebral cortex and 
spinal cord, the microglial reaction was preferentially 
distributed along the pial glia limitans, but in cerebellum, 
reactive cells were distributed at both the pial surface and 
in the subpial parenchyma. With regard to complement 
C9neo staining, 81% of NMO cases exhibited complement 
deposits at the pial surface (Supplementary Figure 5a, 5b; 
Table 2).
Colocalization of microglial activation, AQP4 loss, and 
C9neo deposition at the pia was only observed in NMO tis-
sue and never in controls or MS samples. Furthermore, all 
23 NMO cases exhibited pial and subpial tissue vacuola-
tion characterized by enlarged spaces between astrocytic 
processes (Fig. 2d, n). In some regions, this was coincident 
with dystrophic or hypertrophic astrocytes (Fig. 2e). Sub-
pial calcifications (Fig. 5a, b) and infiltrating inflammatory 
cells (Fig. 5c) were also observed at the pial glia limitans 
in both NMO brain and spinal cord. Focal subpial mye-
lin loss (Fig. 5f) was evident in the brain stem and spinal 
cord white matter, but not in the cortex. In some regions of 
myelin loss, axons were remyelinated by CNS-infiltrating 
Schwann cells (Fig. 5d, e).
Ependyma
The ependyma is formed by a continuous layer of ciliated 
ependymocytes arranged in a simple columnar organization 
that separates the ventricle from the parenchyma (Fig. 6a). 
In normal control tissue ependymal cells expressed abun-
dant AQP4 enriched on the basolateral membrane (Fig. 6c) 
in the absence of reactive microglia (Fig. 6b) or C9neo 
deposition (Fig. 6d). In MS tissue, focal discontinuities in 
the ependymal layer were occasionally observed (Fig. 6e) 
and the ependymocytes present exhibited increased AQP4 
immunoreactivity (Fig. 6g). While subependymal reac-
tive microglia (Fig. 6f) were variably found in MS tissues, 
there was no evidence of C9neo deposition in or near the 
ependyma (Fig. 6h). In contrast, all 16 NMO cases with 
ependymal tissue available for analysis exhibited loss of 
ependymocytes and these discontinuities were typically 
associated with subependymal gliosis and glial nodules 
extending into the ventricle (Fig. 6i). Where the ependymal 
layer remained intact, the cells were frequently character-
ized by an atrophic, flattened morphology, and irregular 
organization (Fig. 6j), including the presence of periven-
tricular ependymal rosettes. This disorganized ependyma 
was also associated with variable eosinophilic infiltration 
(Fig. 6k) and the presence of granulocytes along the CSF 
face of the layer and in the subependymal parenchyma 
(Fig. 6l).
AQP4 immunoreactivity was lost from preserved epend-
ymocytes across multiple blocks among 56% of 16 NMO 
cases with available tissue (Fig. 7a, b), often extending into 
the subependymal parenchyma (Fig. 6o). A combination of 
subependymal astrocyte reactivity with variable astrocyte 
loss was evident in these regions (Supplementary Figure 6). 
In some cases, AQP4 was lost from intact ependymocytes 
but preserved in the parenchyma, suggesting early involve-
ment at the CSF interface (Fig. 6p). All but one of the 16 
NMO cases (94%) also exhibited reactive microglia in the 
ependymal layer (Fig. 6n and Supplementary Figure 7) 
Fig. 2  Pial pathology in NMO. Spinal cord (a–c): Microglial reac-
tivity (arrows) is concentrated at the pial glia limitans (a), colocal-
izing to a region of AQP4 loss (b), and C9neo deposition (c), on con-
secutive sections. Medulla oblongata: (d–i; consecutive sections). The 
subpial parenchyma exhibits mild vacuolation consistent with edema 
(d; H&E), dystrophic astrocytes (e), microglial reactivity (f), C9neo 
deposition (g), loss of AQP4 immunoreactivity (h), and preserved 
myelin (i). Cerebellum (j–o): j Cerebellar meninges contain infiltrat-
ing eosinophils and neutrophils (H&E; enlarged in m) and subpial 
vacuolation (* in m). Reactive microglia are distributed in the subpial 
molecular layer (k; enlarged in n). Subpial AQP4 immunoreactiv-
ity is lost (l; enlarged in o). Normal control: AQP4 immunoreactiv-
ity is abundant at the surface of the spinal cord (p) and cerebellum 
(r). Microglial reactivity is negligible in the normal cerebellum (q). 
Immunohistochemistry for KiM1P (a–c, f; k, n, q); AQP4 (b, h, l, 
o, p, r); C9neo (c, g); GFAP (e); PLP (i). Scale bars in a, b, c, p, q, 
and r = 100 µm. Scale bars in d–i, m-o = 50 µm. Scale bars in j, k, 
l = 200 µm
◂
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and about a third (38%) of cases showed C9neo deposition 
preferentially localized to the ependymocytes (Fig. 6m and 
Supplementary Figure 8).
Choroid plexus
In normal controls, approximately 40% of choroid plexus 
epithelial cells demonstrate AQP4 immunoreactivity in 
the cytoplasm and at the basolateral membrane (Fig. 8a, 
arrows). In general, AQP4 expression was more abundant 
in choroid plexus adjacent to the wall of the fourth ventri-
cle. AQP1 immunoreactivity was more uniform in normal 
choroid plexus and predominantly localized to the epithe-
lial cell apical membrane (Fig. 8b). Compared to normal 
control tissue, the choroid plexus in hydrocephalus cases 
exhibited more pronounced basolateral AQP4 immunore-
activity (Fig. 8c) and increased AQP1 immunoreactivity in 
the cytoplasm and at the apical plasma membrane (Fig. 8d). 
All five papilloma cases showed focal clusters of tumor 
cells with increased AQP4 immunoreactivity in both the 
membrane and cytoplasm, without apparent polarization 
(Fig. 8e). AQP1 immunoreactivity remained polarized to 
the apical membrane in papilloma tissue, but the staining 
pattern was heterogeneous (Fig. 8f). AQP4 immunoreactiv-
ity was normal or increased in MS choroid plexus (Fig. 8g), 
and apical AQP1 immunoreactivity was increased in some 
cases (Fig. 8h). In contrast, in all 12 NMO cases with cho-
roid tissue available, choroid plexus epithelial cells dem-
onstrated a near complete loss of AQP4 immunoreactivity 
(Fig. 8i), whereas AQP1 immunoreactivity was preserved 
(Fig. 8j).
Further analysis of NMO cases confirmed that while 
the gross structure of choroid plexus did not appear dis-
rupted (Fig. 9a), AQP4 immunoreactivity in the choroid 
epithelial cells was reduced or lost from the basolateral 
membrane (Fig. 9b). In contrast, the intact choroid plexus 
Fig. 3  Quantification of pial 
AQP4 immunoreactivity. AQP4 
immunoreactivity in the pia 
was assessed in multiple blocks 
from individual patients (a). A 
range of AQP4 expression was 
observed. Dark blue circles 
enumerate blocks with AQP4 
loss; light blue circles represent 
blocks that showed reduced 
AQP4 but not complete loss, 
and gray circles are blocks with 
normal or increased AQP4. The 
number of NMO cases exhibit-
ing AQP4 loss versus AQP4 
preservation in the pia in at 
least one block was determined 
across anatomical regions and 
expressed as percentages (b)
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in MS cases (Fig. 9g) exhibited normal or increased AQP4 
immunoreactivity (Fig. 9h). The number and size of stro-
mal KiM1P-positive cells were increased in 86% of NMO 
cases (Fig. 9c), while only scattered KiM1P-positive 
macrophages/microglia were observed in the MS cases 
(Fig. 9i). C9neo deposition was observed in perivascular 
regions of the plexus stroma and in stromal concretions in 
both NMO (arrowhead in Fig. 9d) and MS cases (arrow-
head in Fig. 9j). However, extensive C9neo immunoreac-
tivity was exclusively found on the membrane of choroid 
plexus epithelial cells in 40% of NMO cases (Fig. 9d), a 
pattern that was not observed in any of the MS cases. Mem-
brane Ig deposition was present on choroid epithelial cells 
in NMO (Fig. 9e, f), but restricted to the choroid stroma in 
MS (Fig. 9k, l).
Discussion
This study provides the first evidence for involvement 
of CSF–brain and blood–CSF interfaces at the pial glia 
limitans, the ependymal surface, and the choroid plexus in 
the histopathology of NMO (Table 2). At the pial glia limi-
tans, AQP4 loss was colocalized with dystrophic astrocytes, 
microglial reactivity, and C9neo deposition. AQP4 loss at 
the pial surface also colocalized with meningeal infiltration 
of eosinophils and neutrophils. Likewise, the ependymal 
lining of ventricles in NMO tissue exhibited loss of epend-
ymocytes and structural disorganization associated with 
the presence of subependymal reactive astrocytes, loss of 
AQP4 expression at both the ependymal surface and in the 
parenchyma, microglial reactivity, C9neo deposition, and 
granulocytic infiltrates at the CSF face of the ependymal 
layer. Finally, the choroid plexus in NMO tissues exhibited 
profound loss of AQP4 expression, an increase in number 
of stromal macrophages, and deposition of immunoglobu-
lins and complement activation factors on choroid epithe-
lial cell membranes. These changes were never observed 
in control tissues. The specificity of AQP4 loss in the cho-
roid plexus in NMO cases was confirmed by the coinci-
dent retention of normal levels of AQP1 immunoreactivity. 
While MS cases did exhibit microglial reactivity and some 
evidence of stromal complement deposition, the pattern and 
extent of pathology were markedly different from NMO, 
indicating a unique pathology involving CSF interfaces 
Fig. 4  Pattern of pial AQP4 immunoreactivity loss in individual 
NMO patients. Among 21 NMO cases (107 blocks), the pattern of 
pial AQP4 loss was characterized as focal or diffuse. Subjects exhibit-
ing diffuse AQP4 loss were further graded based on the percentage of 
pial involvement ranging from <25%; 25–50%; 50–75%, and >75% 
loss. Each symbol represents one block; symbol shape represents pat-
tern of loss; and color indicates percentage of pia demonstrating dif-
fuse AQP4 loss. Blocks exhibiting both diffuse and focal patterns are 
indicated with a gray line under the color-coded diffuse pattern sym-
bol. Patient identifiers and disease duration are shown on the y-axis
Table 2  Comparison of pathology at CSF–brain and blood–CSF 
interfaces
CDM cortical demyelination
a Epithelial cells in the normal choroid plexus of the fourth ventricle 
express AQP4. In NMO, AQP4 loss was reflected by a decrease in the 




 C9neo deposition Yes (17/21) Yes (2/5) No
 Microglial reaction
  Localized to pia Yes (18/22) Yes No
  Extended into cortex Rare Yes No
  Associated with CDM No No No
 AQP4 loss Yes (21/23) No (increased) No
Ependyma
 C9neo deposition Yes (6/16) Yes (1/5) No
 Microglial reaction Yes (16/16) Scattered (2/5) No
 AQP4 loss Yes (9/16) No (increased) No
 Ependymal discontinuity Yes (16/16) Yes (5/5) Rare
Choroid plexusa
 C9neo deposition
  On epithelial mem-
brane
Yes (4/10) No No
  In stroma Yes Yes Yes (rare)
 Microglial reaction Moderate Mild Minimal
 AQP4 loss Yes (12/12) No (increased) No
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in NMO that mirrors the pathology at blood–brain inter-
faces. Notably, while the glia limitans superficialis and the 
glia limitans perivascularis share a primary involvement of 
AQP4-expressing astrocytic foot processes, the ependymal 
and choroid plexus barriers are comprised of non-astrocytic 
cells expressing AQP4. Thus, while NMO is certainly a 
primary astrocytopathy, the disease also has an important 
component of an “AQP4-opathy” that involves antibody-
mediated injury to other CNS cell types that express the 
water channel. As with our previous report demonstrating 
that sarcolemmal AQP4 is a target of IgG in patients with 
NMO [19], these observations further expand the cellu-
lar repertoire of NMO IgG targets beyond the archetypal 
astrocyte.
Ependymoglial lineage cells exhibit apical-basal polari-
zation and the expression of basolateral membrane spe-
cializations that facilitate contact with mesenchymal bor-
ders [10]. These specializations anchor the basolateral 
membrane of ependymoglial cells to the basal lamina 
of mesenchymal cells via interactions between laminin, 
α-dystroglycan, and β-dystroglycan [73]. Thus, astro-
cytic endfeet interact with capillary endothelial cell and 
meningeal fibroblast basement membranes to form the 
blood–brain barrier and the CSF–brain barrier, respectively 
[69], and choroid plexus epithelial cells interact with cap-
illary endothelial cell basement membranes to form the 
blood–CSF barrier [28, 37]. These physical mesenchy-
mal–ependymoglial barriers are vital to the maintenance 
of the unique CNS interstitial fluid composition required 
for normal neuronal function. Of note, AQP4 is a compo-
nent of the dystrophin-associated protein complex and is, 
therefore, polarized to the basolateral membrane of epend-
ymoglial cells, bringing the water channel into proximity 
with the mesenchymal borders [50]. Indeed, this localiza-
tion is fundamental to water, ion, and protein exchange 
between the blood, the brain parenchyma, and the CSF [1].
The blood–brain barrier is formed at tight junctions 
between capillary endothelial cells within the brain paren-
chyma, preventing diffusion of blood-borne ions and pro-
teins into the perivascular stroma. The endfeet of perivascu-
lar astrocytes, along with accessory cells, such as pericytes, 
provides a second layer of control over solute flow from 
blood to parenchyma, resulting in a two-step process of 
facilitated movement across the endothelial cell barrier 
and then across the astrocyte barrier [69]. In contrast, the 
blood–CSF barrier at the choroid plexus is physically man-
ifested by the apical tight junctions found between choroid 
plexus epithelial cells. The endothelial cells at this inter-
face are fenestrated and lack tight junctions, permitting 
diffusion of ions and proteins into the choroid stroma [74]. 
Pathogenically, this difference has a profound consequence 
for accessibility of NMO IgG to AQP4. At the blood–brain 
Fig. 5  Spectrum of subpial histopathological alterations in NMO. 
Calcifications are observed in the spinal pial glia limitans (a; arrows; 
enlarged in b; H&E). An eosinophil is present in the pial glia limitans 
immediately below the spinal leptomeninges (c; arrow; H&E). Invad-
ing Schwann cells (circled with blue dotted line) are found in the spi-
nal cord at the dorsal root entry zone (d; enlarged in e; H&E). Focal 
subpial myelin loss (circled with blue dotted line) is observed in the 
spinal cord (f; PLP). Scale bars in a, d, and f = 200 µm. Scale bars in 
b and e = 50 µm. Scale bars in c = 10 µm
605Acta Neuropathol (2017) 133:597–612 
1 3
barrier, circulating NMO IgG has limited access to AQP4 
on perivascular astrocytic endfeet. However, at the blood–
CSF barrier, NMO IgG could readily enter the perivascular 
space and encounter AQP4 on the basolateral surface of the 
choroid epithelial cells.
Robust AQP4 expression on the basolateral surface of 
choroid plexus epithelial cells in normal tissue coupled to 
the presence of immunoglobulin immunoreactivity and the 
nearly complete loss of AQP4 expression in these cells in 
NMO tissue indicates that the blood–CSF barrier may be 
a primary site for entry of NMO IgG into the CNS. In fact, 
immunoglobulins have been detected within the choroid 
plexus stroma in healthy normal controls [52], as well as in 
both neurological and non-neurological disease conditions, 
Fig. 6  Ependymal pathology in normal, MS, and NMO tissues. Nor-
mal control: Ependymocytes show ciliated simple columnar mor-
phology lining the ventricle (a). Minimal microglial reactivity is 
present (b), AQP4 immunoreactivity is abundant on ependymocytes 
and in the subependymal parenchyma (c), and C9neo is not detected 
(d). MS: Focal ependymal loss is present in MS (e; arrow). Reac-
tive microglia are found in the subependymal parenchyma but not in 
the ependymal layer (f); AQP4 immunoreactivity is increased at the 
ependyma (g; arrow), but C9neo is not present (h). NMO: Epend-
ymocytes are lost (arrow) and a subependymal glial nodule (arrow-
head) bulges into the ventricle (i). Discontinuous atrophic ependymal 
cells (arrow) are flattened along the ventricle wall (j). Infiltrating 
eosinophils (arrows) are present beneath a disorganized ependy-
mal layer (k). Abundant granulocytes are found on the CSF face of 
preserved ependyma and in subependymal parenchyma (l). C9neo 
immunoreactivity is observed on ependymocytes (m). A consecu-
tive section to (j) demonstrates microglial reactivity (arrows) at the 
ependymal layer (n). AQP4 loss (o) is extensive in both the ependyma 
and subependymal regions of a section consecutive to (k). Focal loss 
of ependymal AQP4 immunoreactivity is observed with preservation 
of subependymal AQP4 (p). Scale bars in a–h = 20 µm. Scale bars in 
i–k, n, and o = 200 µm. Scale bars in l, m, and p = 100 µm. Immu-
nohistochemistry for KiM1P (b, f, n); AQP4 (c, g, o, p); C9neo (d, h, 
m); and H&E (a, e, i–l)
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such as Alzheimer disease, systemic lupus erythematosus, 
and others [3, 4, 9, 13, 17, 46, 55, 56, 66, 67, 81]. Of note, 
we also detected robust immunoreactivity for C9neo at the 
Fig. 7  Quantification of ependymal AQP4 immunoreactivity in 
NMO. AQP4 immunoreactivity in the ependyma was assessed in 
multiple blocks from individual patients (a). A range of AQP4 expres-
sion was observed. Dark blue circles enumerate blocks with AQP4 
loss; light blue circles represent blocks that showed reduced AQP4 
but not complete loss; and gray circles are blocks with normal or 
increased AQP4. Patient identifiers and disease duration are shown on 
the y-axis. The number of NMO cases exhibiting AQP4 loss versus 
preservation in the ependyma in at least one block was determined 
and expressed as a percentage (b)
Fig. 8  Patterns of AQP4 and AQP1 expression in the choroid plexus. 
Normal choroid plexus epithelial cells exhibit variable AQP4 immu-
noreactivity in the basolateral membrane and cytoplasm (a; arrow-
heads highlight positive cells), whereas AQP1 is distributed uni-
formly at the apical membrane in normal choroid plexus epithelial 
cells (b). In hydrocephalus, both AQP4 (c) and AQP1 (d) immuno-
reactivity are increased throughout the choroid epithelium. AQP4 
immunoreactivity is focally increased in papilloma (e; arrowheads), 
while AQP1 expression (f) is more variable and abnormal. In multi-
ple sclerosis, AQP4 immunoreactivity in the choroid plexus is either 
normal or increased (g; arrowheads) with more pronounced AQP1 
immunoreactivity (h). In NMO, AQP4 immunoreactivity is greatly 
reduced or entirely absent in the choroid plexus (i); however, AQP1 
immunoreactivity is normal (j). Scale bars 20 µm. Immunohisto-
chemistry for AQP4 (a, c, e, g, i) and AQP1 (b, d, f, h, j)
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blood–CSF barrier in NMO tissues, with a pattern that sug-
gested deposition along the choroid plexus epithelial cell 
membrane. Complement factors, ranging from C1q through 
to C9neo, are also observed in the choroid plexus in mul-
tiple conditions, including MS and Alzheimer disease [22, 
48, 54–56, 66]. However, in MS, as recently reported by 
Moore et al. [48], deposition of C9neo is observed pre-
dominantly in stromal concretions and at the subepithelial 
basement membrane, with only infrequent staining on cho-
roid epithelial cells. Our study corroborates this finding: 
in Fig. 9j, we show that C9neo is almost entirely restricted 
to subepithelial basement membrane and stromal concre-
tions in MS tissue. What sets NMO apart from the nor-
mal, non-pathogenic deposition of complement within the 
choroid stroma is the presence of AQP4 on the basolateral 
membrane of the epithelial cells adjacent to the basement 
membrane and stroma. Rather than accumulate in concre-
tions, some of the circulating NMO IgG that crosses into 
the choroid stroma may find antigenic target and trigger 
complement deposition on the epithelial cell membranes. 
This is supported by the staining in Fig. 9d, in which 
C9neo is clearly present on the epithelial cell membrane. 
Thus, while immunoglobulin and complement deposition 
in the choroid plexus are not unique to NMO, per se, the 
distribution of these factors beyond the stroma and base-
ment membrane is uniquely driven by the availability of the 
AQP4 target antigen and the presence of anti-AQP4 anti-
body in NMO patients.
The presence of C9neo on choroid epithelial cells raises 
the possibility of complement-mediated damage to the 
Fig. 9  Choroid plexus pathology in NMO and MS. NMO: Intact 
choroid plexus (a; H&E) exhibits extensive AQP4 loss (b) and 
increased macrophage density (c). C9neo deposition is observed in 
stromal concretions (d; arrowhead) but also on choroid epithelial cell 
membranes (d inset; arrow). IgG immunoreactivity is also observed 
in the choroid plexus (e) with intense IgG immunoreactivity on the 
membrane of choroid plexus epithelial cells (f; inset). MS: Choroid 
plexus (g; H&E) shows preserved AQP4 (h). Scattered macrophages 
are found in the stroma (i; arrows), as well as calcifications (i; arrow-
head). C9neo deposition is present in stromal concretions (j; arrow-
head) and in the perivascular basement membrane (j inset; arrow) but 
not on choroid epithelial cell membranes. Diffuse IgG immunoreac-
tivity is observed in the choroid plexus (k), predominantly restricted 
to the stroma and perivascular region (l; arrow; inset). Scale bars in 
a–d, f, g–j, and l = 50 µm. Scale bars in e and k = 100 µm. Immuno-
histochemistry for AQP4 (b, h); KiM1P (c, i); C9neo (d, j); and IgG 
(e, f, k, l)
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choroid as a pathogenic trigger in NMO. However, para-
doxically, while we observed ependymal disorganization 
and discontinuity coincident with C9neo deposition and 
subpial vacuolations associated with C9neo deposition at 
the pial glia limitans, we did not find evidence for overt 
choroid plexus damage. In this context, it is noteworthy 
that AQP4 is also expressed on the basolateral membrane 
of kidney epithelial cells in the distal tubule [72] and is 
accessible to NMO IgG across the peritubular capillary 
endothelial cells in the same manner that it is accessible 
in the choroid plexus [36]. However, kidney pathology 
has not been widely reported in NMO patients, with only 
two studies suggesting possible injury to AQP4-expressing 
tubular epithelial cells, both of which occurred in unu-
sual circumstances [25, 49]. This may be explained by the 
robust expression of complement regulatory factors on the 
basolateral membrane of distal tubule and collecting duct 
cells in the kidney [63]. Choroid plexus epithelial cells 
also express complement regulatory proteins and upregu-
late expression of factors, such as CD46 and CD59 under 
pathogenic conditions [5, 68]. Moreover, several stud-
ies indicate that C9neo deposition, despite being equated 
with obligate lytic destruction in much of the literature, 
can be detected in the absence of damage due to regulation 
of the terminal membrane attack complex by molecules, 
such as vitronectin and clusterin [7, 21]. The expression of 
these molecules in the human choroid plexus is currently 
unknown, but the maintenance of physical integrity at the 
blood–CSF barrier despite heightened C9neo deposition 
suggests that something is preventing lytic destruction. 
Likewise, while we speculate that the blood–CSF barrier 
may serve as a unique entry point for NMO IgG into the 
CNS, it is not clear whether such transmission requires a 
physical compromise of the barrier or whether changes in 
AQP4 expression, microglial activation, and complement 
cascade engagement initiate a functional compromise or 
modulation that permits IgG introduction from the blood 
into the CSF.
If circulating NMO IgG enters the CSF at the choroid 
plexus, it may initiate a cascade of events that eventu-
ally leads to parenchymal astrocyte injury and subsequent 
secondary loss of myelin [39]. Our observation of AQP4 
expression on the basolateral surface of ependymal cells in 
normal tissue and the loss of ependymal AQP4 expression 
in NMO tissue, as well as evidence of ependymal disconti-
nuity and C9neo deposition on ependymal cells, suggests 
that CSF NMO IgG gained access to this CSF–brain barrier 
and elicited damage. Likewise, astrocyte reactivity, loss of 
AQP4 expression, and deposition of C9neo at the pial glia 
limitans, associated with subpial vacuolated tissue, suggest 
that this CSF–brain barrier was also targeted by NMO IgG. 
While ependymal cells along the ventricle are connected by 
intermediate junctions [51] and pial fibroblasts are joined 
by desmosomes [18], neither of these structures are as 
restrictive to IgG diffusion as tight junctions [44]. At these 
sites, NMO IgG would have access to AQP4 expressed on 
the basolateral surface of ependymal cells as well as to 
AQP4 expressed on astrocytic endfeet. Thus, serum NMO 
IgG may gain access to brain parenchyma by transitioning 
through the blood–CSF barrier at the choroid plexus, cir-
culating through the CSF, and then transitioning through 
the CSF–brain barriers at the ependyma and the pial glia 
limitans. Ultimately, this blood-to-CSF-to-brain transition 
of NMO IgG may result in an inside-out antibody-mediated 
compromise of the blood–brain barrier, providing direct 
access of NMO IgG from blood-to-brain. In addition, the 
CSF route for NMO IgG entry into the brain parenchyma 
could generate reactive astrocyte responses that drive gran-
ulocytic infiltration even across an intact blood–brain bar-
rier [23, 77], inducing inflammatory-mediated, leukocyte-
dependent pathology within the parenchyma [40].
Our findings, therefore, suggest a possible pathogenic 
role for NMO IgG in the CSF. NMO IgG is detected in 
CSF and levels are predicted by recent relapse and high 
serum NMO IgG titer [26, 43]. Increased total CSF protein 
and elevated CSF lactate and albumin levels also correlate 
with NMO disease severity and acute relapse, suggesting 
a relationship between dysfunction at the blood–CSF bar-
rier and disability [26, 31, 82]. Conversely, in a study of ten 
NMO patients with CSF NMO IgG measured at relapse, 
follow-up measurements after treatment revealed that a 
reduction in NMO IgG in CSF correlated with clinical 
improvement, though serum levels were not correlated with 
remission [11]. The concept of distinct pathogenic roles for 
CSF and serum NMO IgG is further supported by evidence 
that plasmapheresis showed delayed efficacy in some NMO 
patients, suggesting that the initial washout was insufficient 
to improve function [30, 38]. Together, these findings sup-
port the CSF compartment as an important source of patho-
genic NMO IgG. The cascades elicited by CSF NMO IgG 
likely include the direct induction of complement-mediated 
injury to CSF–brain interfaces and parenchymal astrocytes, 
as well as the initiation of self-amplifying astrocytic stress 
responses, as discussed above. However, an equally impor-
tant mechanism of injury triggered by NMO IgG in the 
CSF may be disruption of normal water homeostasis at the 
blood–CSF and CSF–brain barriers.
Pathologic changes in brain water content manifest 
in two distinct but inter-related ways: edema, associated 
with increased water in the brain parenchyma [71], and 
hydrocephalus, associated with increased water in the 
CSF [8]. Edema is generally categorized as cytotoxic, in 
which reduced water transport function in parenchymal 
cells leads to interstitial shrinkage and intracellular swell-
ing in the absence of blood–brain disruption, or vasogenic, 
in which blood–brain barrier damage induces interstitial 
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accumulation of water. Brain edema is cleared by intersti-
tial or cellular water flow across the glia limitans superficia-
lis into CSF and then into the blood, by water flow across 
the ependyma into the CSF and then into the blood, and by 
flow across the glia limitans perivascularis directly into the 
blood [70]. AQP4 is clearly involved in edema [71], such 
that genetic deletion of AQP4 results in reduced cytotoxic 
edema by limiting the rate of water accumulation in the 
parenchyma, but increased vasogenic edema by reducing 
water clearance at the CSF–brain and blood–CSF barriers 
[62]. In NMO, this suggests that loss of AQP4-expressing 
cells or loss of AQP4 expression at the CSF–brain barrier in 
the ependyma or pial glia limitans will reduce the capacity 
to remove water from the parenchyma, facilitating edema. 
Indeed, evidence of extensive T2-weighted MRI hyperin-
tensities in subcortical white matter coupled to an absence 
of gadolinium enhancement by T1 MRI and an increase 
in the apparent diffusion coefficient indicates the pres-
ence of pseudo-vasogenic interstitial edema in NMO [64]. 
Similar observations of increased apparent diffusion coef-
ficient in normal-appearing white matter in the absence of 
gadolinium enhancement [27] further argue for a pseudo-
vasogenic edema in NMO in which interstitial water is 
increased without blood–brain barrier dysfunction due 
to failure to transport water at CSF–brain interfaces [12]. 
This model is consistent with the loss of AQP4 expression 
and vacuolated underlying tissue observed at these barrier 
sites in NMO, and with our previous report of intramyelinic 
edema [20]. This model also highlights the role of AQP4 
loss at CSF–brain interfaces in the transient edema we pre-
viously described in NMO patients with posterior revers-
ible encephalopathy syndrome [42].
We recently reported that obstructive hydrocephalus is 
found in NMO patients at a higher frequency than observed 
in the general adult population [6]. On the basis of these 
cases, we predicted a primary involvement of ependyma in 
NMO and our current findings support this concept. How-
ever, the pathogenic mechanisms underlying hydrocephalus 
in NMO are not straightforward. While evidence from mice 
lacking AQP4 expression indicates about a 10% incidence 
of hydrocephalus triggered by complete obstruction of the 
cerebral aqueduct [14], it is not clear why such obstruc-
tions occur. AQP4-null mice exhibit an intact blood–brain 
barrier but a disorganized ependymal cell layer, even in 
animals without hydrocephalus [14], supporting a model 
in which loss of AQP4, whether genetic or antibody-medi-
ated, induces defects in CSF homeostasis. However, loss of 
AQP4 at the blood–CSF barrier in the choroid plexus may 
have counteracting effects on CSF production, resulting 
in little change in overall CSF volume. This model argues 
against CSF hyper-production as the cause of hydrocepha-
lus in NMO, though it remains possible that hypo-produc-
tion of CSF due to loss of choroid plexus epithelial cells 
could impact ventricular flow in a manner that increases 
the likelihood of aqueductal blockage. Such blockage and 
subsequent obstructive hydrocephalus may also arise as a 
result of ependymal cell loss induced by the NMO IgG-
mediated complement deposition we observed in this study. 
Humans and mice with primary ciliary dyskinesia exhibit 
hydrocephalus [32], and genetic deletion or mutation of 
multiple specific ciliary proteins results in ependymal cilia 
beat defects and consequent hydrocephalus induced by 
reduced CSF flow [15, 33, 45, 79]. Additional evidence 
indicates that laminar CSF propulsion mediated by ependy-
mal cilia is required to maintain aqueductal patency, and 
defects in such propulsion result in aqueduct stenosis and 
triventricular hydrocephalus [24]. Ultimately, short of cata-
strophic loss of ependymal cells and/or choroid plexus epi-
thelial cells or the initiation of an amplification loop that 
results in a rapid rise in intracerebral pressure and conse-
quent collapse of the aqueduct, it is likely that overt hydro-
cephalus in NMO is at one end of a spectrum that more 
frequently manifests as transient pressure increases and dis-
organized CSF flow. Regardless, these events may contrib-
ute to pathologic events in the brain parenchyma that run 
in parallel to direct NMO IgG-induced astrocyte pathology. 
Indeed, it is possible that preventing damage at the blood–
CSF and CSF–brain interfaces may substantially reduce 
or delay direct parenchymal damage by the NMO IgG. In 
light of this, it is noteworthy that we observed robust com-
plement deposition at the choroid plexus and ependymal 
interfaces, suggesting that these sites may be directly pro-
tected by complement cascade blocking therapies, such as 
eculizumab [57]. It would be of interest in future studies 
to determine if eculizumab therapy alters the imaging hall-
marks of pseudo-vasogenic edema in NMO patients as a 
secondary outcome measure.
The pathology findings we describe also provide mecha-
nistic evidence for our previous report of periependymal 
and periventricular MRI abnormalities [58]. These included 
fluid-attenuated inversion recovery (FLAIR) and T2 sig-
nal abnormalities in periependymal regions of the lateral 
ventricles and along the walls of the third and fourth ven-
tricles and the aqueduct of Sylvius. In meningitis, FLAIR 
hyperintensity is caused by elevated CSF protein con-
tent related to leptomeningeal inflammation [29], which 
extends the effective echo time beyond the inversion time 
used to suppress bulk CSF [47]. This same effect results in 
T2 hyperintensity. Therefore, our previously reported MRI 
findings are consistent with pathological changes at the 
ependymal CSF–brain and choroid plexus blood–CSF bar-
riers that may involve both inflammation (Fig. 6k, l) and 
decreased local CSF flow due to cell injury or loss and bar-
rier breach (Fig. 6i, j). Likewise, the reports of the so-called 
“pencil thin” ependymal hyperintensities with contrast-
enhanced FLAIR imaging [2] support a dynamic alteration 
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or disruption at the CSF–brain barrier. Notably, in com-
mon with infection-induced changes in the ependyma and 
choroid plexus [16], intraventricular exudate (“ventricular 
debris”) may be an expected MRI observation during acute 
attacks in NMO patients and may contribute to a loss of 
aqueduct patency that triggers hydrocephalus [60].
In conclusion, we provide evidence that the interfaces 
between blood and CSF and between CSF and brain are 
key sites for the initiation of NMO pathophysiology. Fur-
thermore, the pathology at these sites may have important 
implications for disease evolution in NMO patients, includ-
ing serving as the possible point at which serum NMO IgG 
enters the CNS and gains broad access to the brain paren-
chyma. Our findings also indicate that NMO is an “AQP4-
opathy” with pathological targets beyond the astrocyte and 
provide insight into recent reports of edema [12, 20, 27, 42, 
64] and hydrocephalus [6] in NMO patients that may sug-
gest a unique model for CSF flow-dependent pathogenic 
events in this disease. Finally, the abundance of comple-
ment activation products in the choroid plexus, pial glia 
limitans, and ependymal layer suggests that these sites may 
be key targets for complement blocking therapies [57]. As 
such, imaging of these interfaces and other measures of CSF 
homeostasis may offer quantifiable tests of efficacy in future 
trials using therapies that target the complement pathway in 
NMO.
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